Drug Patents owned by United Therap

1. Drug name - ORENITRAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050311 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 7 months from now)

US7417070 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2026

(3 years from now)

US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(6 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

CN101265226A UNITED THERAP Compound And Method For Delivery Of Prostacyclin Analogueue
May, 2024

(1 year, 7 months from now)

CN101780092B UNITED THERAP Compounds And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN100558351C UNITED THERAP Composition And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN101265226B UNITED THERAP Composition And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN101780092A UNITED THERAP Compound And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN1822826A UNITED THERAP Compounds And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(6 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(6 years from now)

IN200502621P2 UNITED THERAP An Oral Pharmaceutical Composition
May, 2024

(1 year, 7 months from now)

IN247151B UNITED THERAP An Oral Pharmaceutical Composition
May, 2024

(1 year, 7 months from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

EP1628654B1 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP1628654A4 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP2792353A3 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP1628654A2 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP2792353B1 UNITED THERAP Polymorph Of Treprostinil Diethanolamine Salt
May, 2024

(1 year, 7 months from now)

EP2792353A2 UNITED THERAP Polymorph Of Treprostinil Diethanolamine Salt
May, 2024

(1 year, 7 months from now)

EP1628654B2 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278901 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US9422223 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US8252839 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US7544713 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs Jul, 2024

(1 year, 9 months from now)

US9393203 UNITED THERAP Osmotic drug delivery system Apr, 2026

(3 years from now)

US8410169 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs Feb, 2030

(7 years from now)

US8349892 UNITED THERAP Solid formulations of prostacyclin analogs Jan, 2031

(8 years from now)

US8747897 UNITED THERAP Osmotic drug delivery system Aug, 2031

(8 years from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil; A method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; a method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.125MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

2. Drug name - REMODULIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(6 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(6 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(6 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil Dec, 2024

(2 years from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil Dec, 2024

(2 years from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil Dec, 2024

(2 years from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Sep, 2028

(5 years from now)

US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Sep, 2028

(5 years from now)

US7999007 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Mar, 2029

(6 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
2.5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
10MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
20MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription

3. Drug name - TYVASO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(6 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(6 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(6 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716793 UNITED THERAP Treprostinil administration by inhalation May, 2027

(4 years from now)

US10376525 UNITED THERAP Treprostinil administration by inhalation May, 2027

(4 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation Mar, 2028

(5 years from now)

US9358240 UNITED THERAP Treprostinil administration by inhalation May, 2028

(5 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
0.6MG/ML SOLUTION;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.